Opthea Stock Predictions

Healthcare > Biotechnology

Buy OPT

*Your capital is at risk

$3.41

+0 (+0%)

At Close: Jun 30, 2025

Currently predicting for Mon, 8 Jun 2026

OPT Prediction Chart

OPT Predictions History

BE THE FIRST TO PREDICT

The excellent way of becoming a better trader

Easy to use
Enhance your skills
Predict as many as you like
Request predictions
Gather points

Learn to time your buy and sells

I wonder how good you are and if you can beat me?

Now it is your turn to become professional by doing what professionals do - Exercise

Best regards,

Jim - Co-founder of StockInvest.us [ See tutorial video ]

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for OPT with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT OPTHEA LTD

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by